文献速递中枢神经肿瘤放疗头颈部肿瘤放疗放疗物理与技术

儿童、青少年及年轻成人接受质子束治疗中的幻嗅

Phantosmia Among Pediatric, Adolescent, and Young Adult Patients Receiving Proton Beam Therapy.
PubMed 文献 · Adv Radiat Oncol · 2021-12-25

本回顾性研究纳入2019年8月至2020年12月接受调强质子治疗(IMPT)的≤39岁原发或转移性颅内、颅底、鼻咽或鼻窦肿瘤患者99例,12例(12.1%)报告幻嗅。接受全中枢照射(CSI)的27例中8例(30%)报告幻嗅(OR 7.66,95%CI 2.07-28.34,P=.002);幻嗅均为轻度或中度,所有患者均完成放疗。作者认为医生对幻嗅的认识可能改善患者体验和治疗依从性,需前瞻性研究阐明频率、严重程度和机制。

要点

  • 99例接受IMPT的≤39岁颅内/颅底/鼻咽/鼻窦肿瘤患者中12例(12.1%)报告幻嗅,均为轻度或中度,无重度,全部完成放疗。
  • 接受CSI的27例中8例(30%)报告幻嗅(OR 7.66,95%CI 2.07-28.34,P=.002);同步放化疗与幻嗅发生无关(OR 1.09,95%CI 0.32-3.70,P=.90)。
  • 所有报告幻嗅的患者均接受了嗅区照射,嗅区剂量最低至0.5 Gy;作者认为尤其在接受CSI时医生对幻嗅的认识可能改善患者体验和治疗依从性。

核心结论

  • 在首次评估儿童和年轻成人接受IMPT后放射性幻嗅的研究中,所有受影响患者均接受了嗅区照射。
  • 作者认为医生对幻嗅的认识,尤其在接受CSI的背景下,可能改善患者体验和治疗依从性。
  • 作者指出需要前瞻性研究来阐明幻嗅的频率、严重程度和机制。

研究设计与样本

  • 经机构审查委员会批准的回顾性研究,查询单一笔形束扫描质子中心的电子病历。
  • 纳入2019年8月至2020年12月接受IMPT的≤39岁原发颅内、转移性颅内、颅底、鼻咽或鼻窦肿瘤患者,共99例符合纳入标准。
  • 嗅区定义为包括嗅球和嗅束;幻嗅严重程度按干预使用分级:轻度为无干预,中度为支持治疗,重度为中断放疗。

主要发现

  • 99例中12例(12.1%)报告幻嗅,患者描述感知到「氯味」「西兰花味」「陈水味」「金属味」或「难闻气味」。
  • 报告幻嗅的患者中位年龄17(12-33)岁,66.7%为男性,91.7%为颅内肿瘤,均无既往放疗史。
  • 同步放化疗与幻嗅发生无相关(OR 1.09,95%CI 0.32-3.70,P=.90)。
  • 10例幻嗅患者伴有其他毒性:味觉改变3例、视觉障碍5例、恶心/呕吐7例。
  • 幻嗅为轻度7例、中度5例,所有患者均完成放疗疗程;67%接受CSI,33%接受局灶性脑放疗,嗅区剂量最低至0.5 Gy。

关键数值与推荐

  • 幻嗅严重程度分级:轻度为无干预,中度为支持治疗,重度为中断放疗。
  • 嗅区定义为包括嗅球和嗅束。
  • 接受CSI的27例中8例(30%)报告幻嗅,OR 7.66(95%CI 2.07-28.34,P=.002)。
  • 同步放化疗与幻嗅发生无相关,OR 1.09(95%CI 0.32-3.70,P=.90)。

临床怎么用

  • 作者认为医生对幻嗅的认识,尤其在接受CSI的背景下,可能改善患者体验和治疗依从性。
  • 作者指出需要前瞻性研究来阐明幻嗅的频率、严重程度和机制。

局限性

  • 原文在结论中指出需要前瞻性研究来阐明幻嗅的频率、严重程度和机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Phantosmia, an underreported toxicity of brain radiation therapy (RT), is defined as an olfactory disorder resulting in a malodorous phantom smell. This study aimed to characterize the incidence of phantosmia in patients treated with intensity modulated proton therapy (IMPT). METHODS AND MATERIALS: In this institutional review board-approved retrospective study, the electronic medical record of a pencil beam scanning-only proton center was queried for patients ≤39 years of age who received IMPT for primary intracranial, metastatic intracranial, skull base, nasopharyngeal or sinonasal neoplasms between August 2019 and December 2020. Patient, clinical, and phantosmia-related characteristics were collected. The olfactory region was defined to include the olfactory bulb and tract. Phantosmia severity was graded by intervention use (mild, no intervention; moderate, supportive treatment; severe, RT discontinuation). RESULTS: Ninety-nine patients met the inclusion criteria. Twelve patients (12.1%) reported phantosmia. Patients described perceiving a "chlorine," "broccoli," "stale water," "metallic," or "noxious" smell. Of the patients who reported phantosmia, median age was 17 (12-33) years, 66.7% were male, and 91.7% had intracranial tumors. None of the patients had prior RT. Chemoradiotherapy treatment did not correlate with phantosmia development (odds ratio, 1.09; 95% confidence interval, 0.32-3.70; P = .90). Ten patients experienced accompanying toxicities, including taste changes (n = 3), vision disturbances (n = 5), and nausea/emesis (n = 7). Phantosmia was mild (n = 7) or moderate (n = 5). All patients completed their RT course. Sixty-seven percent received craniospinal irradiation (CSI) while 33% received focal brain RT, with the olfactory region receiving doses as low as 0.5 Gy. Notably, 8 of 27 patients who received CSI (30%) reported phantosmia (odds ratio, 7.66; 95% confidence interval, 2.07-28.34; P = .002). CONCLUSIONS: In the first-ever study examining radiation-induced phantosmia among children and young adults treated with IMPT, all affected patients received irradiation dose to the olfactory region. Physician awareness of phantosmia, especially in the context of CSI, may improve the patient experience and treatment compliance. A prospective study is needed to elucidate frequency, severity, and phantosmia mechanism.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Rosenzweig SJ, Lazarev S, Hasan S, et al. Phantosmia Among Pediatric, Adolescent, and Young Adult Patients Receiving Proton Beam Therapy. Adv Radiat Oncol. 2021. PMID: 35387415. doi:10.1016/j.adro.2021.100881

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。